Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (CELU) is a clinical-stage biotechnology pioneer developing placental-derived cell therapies targeting cancer, immune disorders, and degenerative diseases. This page serves as the definitive source for verified company announcements and research developments.
Access real-time updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides investors with essential updates on Celularity's NK cell therapies, CAR T-cell advancements, and biomaterial innovations while maintaining compliance with financial disclosure standards.
Key updates include earnings reports, manufacturing expansions, intellectual property developments, and peer-reviewed research publications. Bookmark this page for structured access to Celularity's progress in creating off-the-shelf cellular therapies and its bio-banking operations.
Celularity Inc. (Nasdaq: CELU) announced preliminary results from its Phase 1 trial of CYNK-001, targeting relapsed refractory acute myeloid leukemia (R/R AML) and measurable residual disease (MRD) positive AML. In a four-dose regimen of CYNK-001, two of four R/R AML patients achieved an objective response by Day 28, while one of three MRD positive patients reached MRD negativity with a three-dose regimen. The treatment was generally well-tolerated, with no dose-limiting toxicities observed. Following these results, Celularity will refine its trial design for a next-generation NK cell therapy, CYNK-301, focusing on optimizing efficacy. These findings will contribute to advancing NK-cell therapies in a challenging clinical environment.
Celularity Inc. (Nasdaq: CELU) announced that its CEO, Robert Hariri, will deliver a keynote address at the International Precision Medicine Center (IPMC) Conference in Goyang City, South Korea, on April 11-12, 2023. The conference theme, "Beyond Longevity: Live 120 Like 50," will explore advancements in cell and gene therapy that enhance longevity. Dr. Hariri emphasized the need for well-controlled studies to examine the potential benefits of cell therapy in extending lifespan and improving quality of life. The event will also focus on building a global longevity science hub, advancing the field of precision medicine centered on cell therapy.
FAQ
What is the current stock price of Celularity (CELU)?
What is the market cap of Celularity (CELU)?
